AGA1
MCID: ALP061
MIFTS: 51

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 57 29 13 38 72
Androgenetic Alopecia 57 53 25 17 72
Androgenic Alopecia 53 25
Androgenetic Alopecia; Aga 57
Female Pattern Baldness 25
Female Pattern Alopecia 72
Male Pattern Alopecia 25
Male Pattern Baldness 25
Alopecia Androgenetic 55
Pattern Baldness 25
Aga1 57
Aga 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant in males
recessive in females


HPO:

32
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

MedGen 42 C4049090
UMLS 72 C0162311 C0263477 C4049090

Summaries for Alopecia, Androgenetic, 1

Genetics Home Reference : 25 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness. The pattern of hair loss in women differs from male-pattern baldness. In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. Androgenetic alopecia in men has been associated with several other medical conditions including coronary heart disease and enlargement of the prostate. Additionally, prostate cancer, disorders of insulin resistance (such as diabetes and obesity), and high blood pressure (hypertension) have been related to androgenetic alopecia. In women, this form of hair loss is associated with an increased risk of polycystic ovary syndrome (PCOS). PCOS is characterized by a hormonal imbalance that can lead to irregular menstruation, acne, excess hair elsewhere on the body (hirsutism), and weight gain.

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to androgenic alopecia and prostatic hypertrophy. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Fenugreek and Fenugreek seed meal have been mentioned in the context of this disorder. Affiliated tissues include prostate, ovary and skin, and related phenotypes are alopecia and endocrine/exocrine gland

NIH Rare Diseases : 53 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Mutations in the AR gene have also been associated with androgenetic alopecia.

OMIM : 57 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200)

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 351)
# Related Disease Score Top Affiliating Genes
1 androgenic alopecia 33.3 SHBG CYP19A1 AR
2 prostatic hypertrophy 31.0 CYP19A1 AR
3 hyperandrogenism 30.6 SHBG CYP21A2 CYP19A1
4 gynecomastia 30.5 SHBG CYP19A1 AR
5 prostatic hyperplasia, benign 30.4 SRD5A2 SRD5A1 SHBG AR
6 prostate disease 30.0 SRD5A1 CYP19A1 AR
7 polycystic ovary syndrome 29.7 SRD5A1 SHBG CYP21A2 CYP19A1
8 prostate cancer 27.1 XIAP SRD5A2 SRD5A1 SHBG CYP19A1 CFLAR
9 aspartylglucosaminuria 12.7
10 lysosomal storage disease 11.6
11 marie unna congenital hypotrichosis 11.5
12 alopecia 11.5
13 angiokeratoma 11.4
14 hypotrichosis 1 11.4
15 hypotrichosis simplex 11.4
16 fucosidosis 11.3
17 galactosemia 11.3
18 mannosidosis, alpha b, lysosomal 11.3
19 lysosomal disease 11.3
20 glucocorticoid resistance, generalized 11.3
21 rapidly involuting congenital hemangioma 10.9
22 alopecia areata 10.8
23 neurofibromatosis, type ii 10.7
24 impotence 10.7
25 telogen effluvium 10.6
26 sexual disorder 10.6
27 prostatic adenoma 10.6
28 lipid metabolism disorder 10.4
29 frontal fibrosing alopecia 10.4
30 lichen planopilaris 10.4
31 hermaphroditism 10.4 SRD5A2 AR
32 hair disease 10.4
33 47, xxy 10.4 SHBG AR
34 diffuse alopecia areata 10.3
35 contact dermatitis 10.3
36 skin disease 10.3
37 seborrheic dermatitis 10.3
38 postmenopausal atrophic vaginitis 10.3 SHBG AR
39 celiac disease 1 10.3
40 inflammatory bowel disease 10.3
41 arteries, anomalies of 10.3
42 autoimmune disease 10.3
43 lipoid congenital adrenal hyperplasia 10.3
44 body mass index quantitative trait locus 1 10.3
45 coronary heart disease 1 10.3
46 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.3
47 hyperlipoproteinemia, type iii 10.3
48 infant gynecomastia 10.3
49 coronary artery anomaly 10.3
50 hypertrichosis 10.3

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Human phenotypes related to Alopecia, Androgenetic, 1:

32
# Description HPO Frequency HPO Source Accession
1 alopecia 32 HP:0001596

Symptoms via clinical synopsis from OMIM:

57
Hair:
early baldness

Clinical features from OMIM:

109200

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Fenugreek Phase 4
2 Fenugreek seed meal Phase 4
3
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
4
Zinc Approved, Investigational Phase 1, Phase 2 7440-66-6 32051
5
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
6
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
7
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
8
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
9
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54670067 5785
10
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
11 Micronutrients Phase 1, Phase 2
12 Nutrients Phase 1, Phase 2
13 Trace Elements Phase 1, Phase 2
14 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
15 Adjuvants, Immunologic Phase 2
16 Anti-Infective Agents Phase 2
17 Protective Agents Phase 1, Phase 2
18 Radiation-Protective Agents Phase 2
19 Antiviral Agents Phase 2
20 Antioxidants Phase 1, Phase 2
21 Chelating Agents Phase 1, Phase 2
22 Zinc Supplement Phase 1, Phase 2
23 Peripheral Nervous System Agents Phase 1, Phase 2
24 Respiratory System Agents Phase 1, Phase 2
25 Free Radical Scavengers Phase 1, Phase 2
26 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
27 Autonomic Agents Phase 1, Phase 2
28 Anti-Asthmatic Agents Phase 1, Phase 2
29 Bronchodilator Agents Phase 1, Phase 2
30 Cholinergic Agents Phase 2
31 abobotulinumtoxinA Phase 2
32 Acetylcholine Release Inhibitors Phase 2
33 Neurotransmitter Agents Phase 2
34 Botulinum Toxins Phase 2
35 Botulinum Toxins, Type A Phase 2
36 HIV Protease Inhibitors Phase 2
37
protease inhibitors Phase 2
38 Proteasome Inhibitors Phase 2
39 Ophthalmic Solutions Phase 2
40 Tranquilizing Agents Phase 2
41 Central Nervous System Depressants Phase 2
42 GABA Agents Phase 2
43 Psychotropic Drugs Phase 2
44 Anticonvulsants Phase 2
45 Antimanic Agents Phase 2
46 Mitogens Phase 1, Phase 2
47 Immunologic Factors Phase 1, Phase 2
48 Complement Factor H Phase 1, Phase 2
49 Complement System Proteins Phase 1, Phase 2
50 Immunosuppressive Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 123)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
3 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
4 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
5 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
6 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
7 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
8 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
9 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
10 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
11 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
12 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
13 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
14 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
15 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
16 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
17 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
18 A Double-Blind, Randomized, Clinical Trial of the Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Healthy Male Subjects With Androgenetic Alopecia Active, not recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
19 H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis Withdrawn NCT02548117 Phase 3 Finasteride
20 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
21 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
22 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
23 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
24 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
25 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
26 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
27 A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement Unknown status NCT01662089 Phase 1, Phase 2 15 mg Chelate zinc supplement;Placebo drug supplement
28 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
29 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
30 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451190 Phase 2
31 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects. Completed NCT01451177 Phase 2
32 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451151 Phase 2
33 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451138 Phase 2
34 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil Completed NCT01451125 Phase 2
35 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451112 Phase 2
36 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
37 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451073 Phase 2
38 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451047 Phase 2
39 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
40 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2
41 Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial Completed NCT02503852 Phase 2
42 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
43 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
44 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
45 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
46 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2
47 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
48 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
49 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
50 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Finasteride
Minoxidil

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Genetic tests related to Alopecia, Androgenetic, 1:

# Genetic test Affiliating Genes
1 Alopecia, Androgenetic, 1 29

Anatomical Context for Alopecia, Androgenetic, 1

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

41
Prostate, Ovary, Skin, Heart, Testes, Bone, Breast

Publications for Alopecia, Androgenetic, 1

Articles related to Alopecia, Androgenetic, 1:

(show top 50) (show all 1314)
# Title Authors PMID Year
1
Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. 38 8
18304493 2008
2
The hairless gene in androgenetic alopecia: results of a systematic mutation screening and a family-based association approach. 38 8
11966690 2002
3
Androgenetic alopecia in heterozygous carriers of a mutation in the human hairless gene. 38 8
10827399 2000
4
The inheritance of common baldness: two B or not two B? 38 8
6512048 1984
5
Genetic analysis of male pattern baldness and the 5alpha-reductase genes. 8
9620288 1998
6
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 8
7849715 1994
7
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 8
8334753 1993
8
Patterned loss of hair in man; types and incidence. 8
14819896 1951
9
Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. 9 38
19663790 2009
10
Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. 9 38
19373488 2009
11
Evaluation of androgen receptor gene as a candidate gene in female androgenetic alopecia. 9 38
19538365 2009
12
Androgen receptor copy number variation and androgenetic alopecia: a case-control study. 9 38
19340294 2009
13
Finasteride treatment and neuroactive steroid formation. 9 38
19655698 2009
14
Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old. 9 38
18363752 2008
15
Men with Kennedy disease have a reduced risk of androgenetic alopecia. 9 38
17596176 2007
16
Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. 9 38
17256155 2007
17
[Premature androgenetic alopecia in adult male with nonclassic 21-OH deficiency. A novel nonsense CYP21A2 mutation (Y336X) in 2 affected siblings]. 9 38
17145028 2006
18
A new look at the 5alpha-reductase inhibitor finasteride. 9 38
16834758 2006
19
The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. 9 38
15824176 2005
20
Solubilization and solid-state characterization of a poorly soluble 5-alpha reductase inhibitor. 9 38
15285330 2004
21
Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. 9 38
14729013 2004
22
Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. 9 38
14528059 2003
23
Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. 9 38
12670724 2003
24
Male-pattern baldness is common in men with X-linked recessive ichthyosis. 9 38
14571075 2003
25
Acne: effect of hormones on pathogenesis and management. 9 38
12358558 2002
26
Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. 9 38
11886493 2001
27
Androgen responsive genes as they affect hair growth. 9 38
11399535 2001
28
The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. 9 38
11125319 2000
29
[Hormonal profile in men with premature androgenic alopecia]. 9 38
10953626 2000
30
[Treatment of androgenetic alopecia in the man using systemic 5 alpha-reductase inhibition]. 9 38
9879479 1998
31
Delayed telogen replacement in a boy's scalp. 9 38
9873170 1998
32
Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. 9 38
9284093 1997
33
Hormonal status in postmenopausal androgenetic alopecia. 9 38
1478763 1992
34
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. 38
30843235 2019
35
Shedding light on the FDA's 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia. 38
30252550 2019
36
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. 38
31403367 2019
37
Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial. 38
30569416 2019
38
Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. 38
30617027 2019
39
The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future. 38
30300013 2019
40
Pediatric Androgenetic Alopecia: a Review. 38
31415838 2019
41
Efficacy of platelet-rich plasma in androgenetic alopecia patients. 38
30393988 2019
42
An overview of herbal alternatives in androgenetic alopecia. 38
30980598 2019
43
Androgenetic alopecia and microneedling: Every needling is not microneedling. 38
30905794 2019
44
Investigation on Microecology of Hair Root Fungi in Androgenetic Alopecia Patients. 38
31240449 2019
45
Do Kimchi and Cheonggukjang Probiotics as a Functional Food Improve Androgenetic Alopecia? A Clinical Pilot Study. 38
31385480 2019
46
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. 38
31054970 2019
47
Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. 38
31400254 2019
48
A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. 38
30566260 2019
49
Finasteride Enhances Stem Cell Signals of Human Dermal Papilla Cells. 38
31280211 2019
50
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. 38
30785992 2019

Variations for Alopecia, Androgenetic, 1

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 STS SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 organelle membrane GO:0031090 9.13 SRD5A2 SRD5A1 CYP21A2
3 cell body fiber GO:0070852 8.32 SRD5A1

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.67 STS SRD5A2 SRD5A1 CYP21A2
2 cell-cell signaling GO:0007267 9.61 SRD5A2 AR
3 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.61 CFLAR AR
4 cellular response to estradiol stimulus GO:0071392 9.6 SRD5A1 CFLAR
5 cellular response to dexamethasone stimulus GO:0071549 9.59 SRD5A1 CFLAR
6 sterol metabolic process GO:0016125 9.58 CYP21A2 CYP19A1
7 male genitalia development GO:0030539 9.58 SRD5A2 SRD5A1
8 uterus development GO:0060065 9.57 TGFB2 CYP19A1
9 male gonad development GO:0008584 9.56 TGFB2 SRD5A2 SRD5A1 AR
10 androgen biosynthetic process GO:0006702 9.55 SRD5A2 SRD5A1
11 cellular response to testosterone stimulus GO:0071394 9.54 SRD5A1 AR
12 prostate gland growth GO:0060736 9.52 CYP19A1 AR
13 testosterone biosynthetic process GO:0061370 9.51 SRD5A2 CYP19A1
14 sex differentiation GO:0007548 9.5 SRD5A2 SRD5A1 AR
15 androgen catabolic process GO:0006710 9.46 SRD5A1 CYP19A1
16 positive regulation of integrin biosynthetic process GO:0045726 9.43 TGFB2 AR
17 response to testosterone GO:0033574 9.4 SRD5A1 CFLAR
18 androgen metabolic process GO:0008209 9.33 SRD5A2 SRD5A1 CYP19A1
19 hypothalamus development GO:0021854 9.26 SRD5A1
20 steroid biosynthetic process GO:0006694 9.26 SRD5A2 SRD5A1 CYP21A2 CYP19A1
21 response to follicle-stimulating hormone GO:0032354 9.19 SRD5A1
22 steroid catabolic process GO:0006706 9.18 STS
23 female genitalia development GO:0030540 8.62 SRD5A1 CYP19A1

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 SRD5A2 SRD5A1 CYP21A2 CYP19A1
2 steroid hydroxylase activity GO:0008395 9.4 CYP21A2 CYP19A1
3 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.37 SRD5A2 SRD5A1
4 androgen binding GO:0005497 9.32 SHBG AR
5 cholestenone 5-alpha-reductase activity GO:0047751 9.26 SRD5A2 SRD5A1
6 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.96 SRD5A2 SRD5A1
7 amide binding GO:0033218 8.85 SRD5A1
8 steroid binding GO:0005496 8.8 SHBG CYP21A2 AR

Sources for Alopecia, Androgenetic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....